Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 12/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 4/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078610 | 0.88 | PIM1 (0.37) | PIM1PIM3PIM2CTSA | |
| SCHEMBL12077217 | 0.86 | PIM1 (0.38) | PIM1PIM3PIM2ECE1CTSA | |
| SCHEMBL319157 | 0.82 | PIM1 (0.44) | PIM1PIM3PIM2CTSAAKR1C3 | |
| SCHEMBL12687456 | 0.81 | PIM1 (0.39) | PIM1PIM3PIM2ECE1AKR1C3 | |
| SCHEMBL29600666 | 0.80 | CAMKK1 (0.41) | PIM1PIM3PIM2KDM4E | |
| SCHEMBL12078221 | 0.80 | CAMKK1 (0.41) | PIM1PIM3PIM2KDM4E | |
| SCHEMBL12079005 | 0.79 | PIM1 (0.35) | PIM1PIM3PIM2AKR1C3AKR1C2 | |
| SCHEMBL12078753 | 0.78 | AKR1C3 (0.36) | PIM1PIM3PIM2ECE1AKR1C3 | |
| SCHEMBL12697097 | 0.78 | RXRA (0.36) | PIM1PIM3PIM2PRKAG1PRKAA1 | |
| SCHEMBL18259230 | 0.78 | PIM2 (0.41) | PIM1PIM3PIM2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | claimed |
| EP-2681195-A1 | NOVEL KINASE INHIBITORS | Novartis AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | PIM1 2184/4885PIM3 2224/4885PIM2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.